12 results
Algorithm for the Evaluation of Anemia #Diagnosis #EM #IM #Honc #Anemia #Differential #Workup #Algorithm #Microcytic #Macrocytic
Anemia #Diagnosis #EM ... #IM #Honc #Anemia
Evaluation of Lymphadenopathy - Localized vs Generalized #Diagnosis #EM #IM #Honc #Lymphadenopathy #Localized #Generalized #Infectious #Malignancy
Generalized #Diagnosis #EM ... #IM #Honc #Lymphadenopathy
Algorithm to decrease AFib admissions - Visual Abstract by hellomynameisDrKirsty
@KirstyChallen

Source: Implementation of a Novel Algorithm to
Algorithm to decrease AFib ... Department With Atrial ... /acem.13383 #AFib ... Algorithm #Management #Atrial ... VisualAbstract #EBM
The arrows point to a subendocardial region with poor contrast enhancement due to ischemia. This is
#Clinical #EM #IM ... Subendocardial #Ischemia #Axial
Typical ECG changes in acute pericarditis includes: stage 1 - diffuse, positive, ST elevations with reciprocal
leads indicates atrial ... inverted #Diagnosis #EM ... #IM #Cardiology
PARIS Trial: A Randomized Trial of High-Flow Oxygen Therapy in Infants with Bronchiolitis
#EBM #Peds #Pediatrics #Bronchiolitis
PARIS Trial: A Randomized ... Trial of High-Flow ... Bronchiolitis #EBM ... HighFlowNasalCannula #HFNC
Immunosuppressive Strategies for the Prevention or Treatment of Acute GVHD. Panel A shows several classic immunosuppressive
tested in clinical trials ... Pathophysiology #IM ... #Honc #Pharm #GVHD
LOWMAGHI - Magnesium for Afib Rate Control

LOw dose MAGnesium sulfate versus HIgh dose in the early
Magnesium for Afib ... management of rapid atrial ... LOWMAGHI #Magnesium #Afib ... #Atrial #Fibrillation ... #EBM #VisualAbstract
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation (RE-DUAL PCI trial) - Shown is
Dabigatran after PCI in Atrial ... Fibrillation (RE-DUAL PCI trial ... warfarin (Panel A) #EBM ... #Cardiology #IM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Adverse Events in the Safety Population, According
, According to Trial ... Group #EBM #Neuro ... #IM #Fremanezumab